The use of extracorporeal membrane oxygenation as a supportive modality for patients with COVID-19 pneumonia emerged as the gold standard of care for those who do not respond to traditional therapies. The primary aim of this 10-month, quantitative, retrospective, quality improvement project was to identify if V-V ECMO treatment guidelines, implemented in the treatment of COVID-19 pneumonia, led to decreased mortality rates and lengths of stay. A total of 27 patients met inclusion criteria during queried time frames (n = 14 in Wave 1 and n = 13 in Wave 2). Data collected demonstrated no significant difference (p = .385) in mortality in Wave 1 and Wave 2. Length of stay was significantly longer for Wave 2 (p = .026). Statistically significant differences were identified in four clinical characteristics: inhaled vasodilator utilization (p < .001), remdesivir utilization (p = .004), days to mechanical ventilation (p = .009), and CRRT hours (p = .026). Further research is required to determine if the results of this study are comparable to larger studies with similar treatment guidelines.
Branco, Chantal, "Mortality and Length of Stay in Patients with COVID-19 on ECMO: A Retrospective Before and After Quality Improvement Study" (2023). DNP Scholarly Projects. 23.